Home › Therapeutic areas › Cardiovascular
Cardiovascular (23 companies · 23 conditions)
Conditions
Pulmonary Arterial Hypertension 4 Rare Pulmonary Hypertension Associated with Interstitial Lung Disease 4 Rare Atherosclerotic Cardiovascular Disease 3 Dilated Cardiomyopathy 3 Heart Failure 3 Hypertension 3 Arrhythmogenic Cardiomyopathy 2 Rare ATTR Amyloidosis 2 Rare Hypertrophic Cardiomyopathy 2 Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction 2 Rare Atrial Fibrillation 1 Catecholaminergic Polymorphic Ventricular Tachycardia 1 Rare Danon Disease 1 Rare Desmoplakin Cardiomyopathy 1 Rare Familial Chylomicronemia Syndrome 1 Rare Hereditary Hemorrhagic Telangiectasia 1 Rare Heterozygous Familial Hypercholesterolemia 1 Homozygous Familial Hypercholesterolemia 1 Rare Hyperlipidemia 1 Hypoplastic Left Heart Syndrome 1 Rare Myocarditis 1 Rare Paroxysmal Supraventricular Tachycardia 1 Pericarditis 1
Companies
| Ticker | Company | Therapeutic areas | In Cardiovascular | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| BIOA | BioAge Labs | CardiovascularOphthalmology | 1 | Phase 2 | $234M | 2 |
| CRDL | Cardiol Therapeutics | Cardiovascular Rare | 4 | Phase 3 | $124M | 4 |
| EWTX | Edgewise Therapeutics | Cardiovascular | 3 | Phase 2 | $4.60B | 3 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $16.7B | 23 |
| GOSS | Gossamer Bio | Cardiovascular Rare | 4 | NDA Submitted | $67.5M | 4 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 2 | Approved | $26.7B | 15 |
| NTLA | Intellia Therapeutics | CardiovascularImmunology Rare | 2 | NDA Submitted | $1.37B | 3 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 5 | Approved | $4.49B | 29 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 3 | Phase 2 | $236M | 12 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 5 | Approved | $5.11B | 9 |
| LGVN | Longeveron | CardiovascularNeurology Rare | 2 | Phase 2 | $7.1M | 3 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 1 | Approved | $1.54B | 5 |
| MIST | Milestone Pharmaceuticals | Cardiovascular | 2 | Approved | $51.4M | 2 |
| MLYS | Mineralys Therapeutics | CardiovascularRenal+1 | 1 | NDA Submitted | $1.28B | 3 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $775M | 7 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 3 | NDA Submitted | $2.33B | 6 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 1 | Phase 3 | $4.7M | 11 |
| RCKT | Rocket Pharmaceuticals | CardiovascularImmunology Rare | 3 | Approved | $236M | 4 |
| SLDB | Solid Biosciences | CardiovascularNeurology Rare | 4 | Phase 3 | $695M | 6 |
| TECX | Tectonic Therapeutic | Cardiovascular Rare | 4 | Phase 2 | $401M | 4 |
| TENX | Tenax Therapeutics | Cardiovascular Rare | 2 | Phase 3 | $64.7M | 2 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularMetabolic+1 Rare | 1 | Approved | $1.70B | 10 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $230M | 27 |
No companies match.